Curaleaf International, in collaboration with Jupiter Research, has secured European Union medical device certification for the first handheld liquid inhalation device specifically designed for precise medical cannabis administration. This regulatory approval represents a significant advancement in medical cannabis delivery technology and establishes new standards for patient care.
The device, now certified as a Class IIa medical device under Regulation (EU) 2017/745, successfully met the EU's stringent regulatory requirements. A recognized EU Notified Body thoroughly assessed and approved the comprehensive technical file and full EU Declaration of Conformity, validating the device's quality, safety, and clinical effectiveness.
Innovative Technology for Precise Dosing
The newly certified inhalation device incorporates advanced features designed to enhance the medical cannabis administration experience. It includes a magnetic snap-in cartridge system and a rechargeable power supply, engineered specifically to deliver consistent and controlled cannabinoid dosing. This precision addresses a critical need in medical cannabis treatment, where accurate dosing remains a significant challenge for healthcare providers and patients.
Boris Jordan, Chairman and CEO of Curaleaf, emphasized the significance of this achievement: "Achieving EU medical certification is more than a regulatory milestone—it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment."
Global Market Implications
The EU certification supports deployment in multiple international markets. Once commercialized, healthcare professionals will be able to recommend the device in various regions including European countries, the United Kingdom, Canada, and across Australasia. This broad market access positions Curaleaf International at the forefront of the global medical cannabis industry.
Tim Conder, Chief Executive Officer of TILT Holdings (parent company of Jupiter Research), highlighted the collaborative nature of this achievement: "Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the US. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionize healthcare. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry."
Strategic Expansion and Market Leadership
This development reinforces Curaleaf International's strategic position and ongoing expansion efforts across Europe and other international markets. The company has been actively strengthening its European presence, recently expanding into the Czech Republic through a partnership with Astrasana Pharma and being announced as the Headline Partner for the Cannabis Europa conference in London.
Curaleaf International maintains a comprehensive network that includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.
Advancing Medical Cannabis Legitimacy
The certification represents more than just a new product approval—it signals the increasing legitimacy and mainstream acceptance of medical cannabis as a therapeutic option. By meeting the same rigorous standards applied to traditional medical devices, this inhalation technology helps bridge the gap between conventional pharmaceuticals and cannabis-based medicines.
For patients, the device promises improved treatment options with greater consistency, potentially enhancing therapeutic outcomes and reducing unwanted variability in dosing. For healthcare providers, it offers a medically approved method to prescribe cannabis with greater confidence in dosing precision.
As the medical cannabis industry continues to mature globally, innovations like this EU-certified inhalation device will likely play a crucial role in shaping treatment protocols and expanding access to cannabis-based therapies. Curaleaf International's achievement marks an important step toward the full integration of medical cannabis into mainstream healthcare systems worldwide.
